REVITALIZE: A telehealth program to help adults with advanced ovarian cancer manage fatigue while on PARP inhibitors
Randomized trial of REVITALIZE: A telehealth intervention to reduce fatigue interference among adults with advanced ovarian cancer on PARP inhibitors
['FUNDING_R01'] · DANA-FARBER CANCER INST · NIH-11077229
This program offers a telehealth approach to help adults with advanced ovarian cancer feel less tired and improve their quality of life while taking PARP inhibitor medications.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11077229 on ClinicalTrials.gov |
What this research studies
Many people with advanced cancer live longer thanks to new treatments, but these treatments, like PARP inhibitors for ovarian cancer, can cause significant fatigue. While other therapies have helped with fatigue in early-stage cancer, there isn't much strong evidence for advanced cancer. This program, called REVITALIZE, uses telehealth to help you manage how much fatigue interferes with your daily life, rather than trying to eliminate it completely. We want to see if this approach can make a real difference in how you feel and potentially help you stick with your cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates are adults aged 21 and older with advanced ovarian cancer who are currently taking PARP inhibitor medications and experiencing fatigue.
Not a fit: Patients who are not experiencing fatigue or are not on PARP inhibitor treatment for advanced ovarian cancer may not receive direct benefit from this specific program.
Why it matters
Potential benefit: If successful, this program could significantly reduce the impact of fatigue on daily life for patients with advanced ovarian cancer and potentially improve their ability to continue life-extending treatments.
How similar studies have performed: While cognitive behavioral therapy has shown success for fatigue in early-stage cancer, this specific telehealth approach for advanced ovarian cancer patients on PARP inhibitors is a novel and refined intervention that has been piloted.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WRIGHT, ALEXI A — DANA-FARBER CANCER INST
- Study coordinator: WRIGHT, ALEXI A
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, Cancer Patient, Cancer Survivor, Cancer Treatment, Cancers